Skip to main content
    E

    Elevance Health Inc (ELV)

    Official site

    HEALTHCARE • HEALTHCARE PLANS • NYSE

    $433.98
    -12.30 (-2.76%)

    Market Cap: $92.84B

    Last updated: Nov 17, 2026 at 4:38 PM ET

    Elevance Health Inc (ELV) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Elevance Health (ELV) has a market cap of $92.84B and an enterprise value of $113.25B. Its share count is down 2.78% from a year earlier.

    Total Valuation

    Enterprise value is 21.98% above the market cap, as debt exceeds cash.

    Market Cap$92.84B
    Enterprise Value$113.25B
    Latest price (Nov 17, 2026)$433.98

    Key Dates

    The next earnings report is expected on Jan 26, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Dec 4, 2026.

    Next Earnings DateJan 26, 2027 (expected)
    Last Earnings DateOct 21, 2026
    Next Ex-Dividend DateDec 4, 2026
    Next Payment DateDec 18, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.38% in the quarter ended Sep 30, 2026 and shrank 3.48% a year over 2 years.

    Shares Outstanding216.06M
    Shares Change (YoY)-2.78%
    Shares Change (QoQ)-0.38%
    Share Count Growth (2Y CAGR)-3.48%

    Valuation Ratios

    Sales and book value multiples are 0.5x and 2.1x. Its year-end P/E ranged from 11.2x to 18.8x from 2016 to 2025.

    P/E Ratio14.3x
    Forward P/E14.8x
    P/S Ratio0.5x
    Forward P/S0.5x
    P/B Ratio2.1x
    P/TBV Ratio17.2x
    P/FCF Ratio14.4x
    P/OCF Ratio12.2x
    PEG Ratio1.7

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 12.4x EBITDA and 17.5x free cash flow.

    EV / Earnings22.2x
    EV / Sales0.6x
    EV / EBITDA12.4x
    EV / EBIT14.7x
    EV / FCF17.5x

    Price Statistics

    The stock is up 35.27% over 52 weeks and trades 4.13% above its 50-day average.

    Beta (1Y)0.27
    52-Week Change+35.27%
    1-Month Change+0.87%
    3-Month Change+9.37%
    6-Month Change+8.79%
    5-Year Change-3.46%
    10-Year Change+244.72%
    Total Return (1Y)+37.41%
    Total Return (3Y CAGR)-0.62%
    Total Return (5Y CAGR)+1.77%
    Return vs SPY (1Y)+24.25%
    Max Drawdown (1Y)-26.49%
    Max Drawdown (3Y)-50.38%
    Sharpe Ratio (1Y)0.87
    Correlation with SPY (1Y)0.11
    50-Day Average$416.78
    200-Day Average$374.81
    52-Week Range$270.87 to $450.69
    RSI (14 Days)55.2
    Average Volume (20 Days)1.41M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.47x current liabilities, and total debt is 0.69x shareholder equity.

    Current Ratio1.47x
    Quick Ratio1.47x
    Debt / Equity0.69x
    Debt / EBITDA3.35x
    Debt / FCF4.72x
    Interest Coverage5.33x

    Returns and Efficiency

    Return on invested capital is 8.33% over the last 12 months, against a 5-year average of 10.26%.

    Return on Equity (ROE)11.42%
    Return on Assets (ROA)3.99%
    Return on Invested Capital (ROIC)8.33%
    Return on Capital Employed (ROCE)9.48%
    ROE (5Y Average)15.18%
    ROA (5Y Average)5.46%
    ROIC (5Y Average)10.26%
    Asset Turnover1.61x
    Receivables Turnover15.36x

    Taxes

    Income tax took 18.35% of pretax income over the last 12 months.

    Income Tax (TTM)$1.15B
    Effective Tax Rate18.35%

    Scores

    ELV has an Altman Z-Score of 3.07, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score3.07
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $201.83B over the last 12 months is up 3.60% from the 12 months before.

    Revenue$201.83B
    Revenue Growth (YoY)+3.60%
    Gross Profit$31.23B
    Operating Income$7.70B
    Pretax Income$6.25B
    Net Income$5.10B
    EBITDA$9.18B
    EBIT$7.70B
    Reported EPS (TTM)$30.35

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 34.96% of the $127.80B in total assets.

    Cash and Equivalents$10.35B
    Total Debt$30.76B
    Net Debt$20.41B
    Net Debt Per Share$94.46
    Working Capital$21.86B
    Shareholder Equity$44.68B
    Book Value Per Share$206.80
    Tangible Book Value$5.46B
    Tangible Book Per Share$25.28
    Total Assets$127.80B
    Total Liabilities$83.01B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.08B of capital spending, operating cash flow left $6.51B of free cash flow.

    Operating Cash Flow$7.60B
    Capital Expenditures$1.08B
    Free Cash Flow$6.51B
    FCF Per Share$30.04
    Depreciation and Amortization$1.49B
    Dividends Paid$1.50B
    Share Repurchases$2.16B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 3.81%, against a 5-year average of 5.19%.

    Gross Margin15.47%
    Operating Margin3.81%
    Pretax Margin3.10%
    Net Margin2.53%
    EBITDA Margin4.55%
    EBIT Margin3.81%
    FCF Margin3.23%
    Gross Margin (5Y Average)14.59%
    Operating Margin (5Y Average)5.19%
    Net Margin (5Y Average)3.58%

    Growth

    Revenue grew 8.34% a year over 3 years, and EPS 1.27% a year.

    Revenue Growth (3Y CAGR)+8.34%
    Revenue Growth (5Y CAGR)+10.32%
    EPS Growth (3Y CAGR)+1.27%
    EPS Growth (5Y CAGR)+6.12%
    FCF Growth (3Y CAGR)-24.06%
    FCF Growth (5Y CAGR)-19.97%
    Operating Income Growth (3Y CAGR)-1.36%

    Revenue and profit by year

    Dividends and Yields

    ELV pays out 19.54% of earnings as dividends.

    Dividend Per Share (Annual)$6.88
    Dividend Yield1.59%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+10.14%
    Dividend Growth (5Y CAGR)+12.47%
    Payout Ratio19.54%
    FCF Payout Ratio23.01%
    Earnings Yield6.99%
    FCF Yield6.95%
    Buyback Yield2.30%
    Shareholder Yield3.90%

    Full dividend history

    Stock Splits

    The last split was a 2-for-1 forward split on Jun 1, 2005.

    Last Split DateJun 1, 2005
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 12 similar companies, ELV has the 9th highest P/E and the 6th highest P/S.

    P/E Ratio14.3x vs 28.4x median
    P/S Ratio0.5x vs 0.3x median
    ROIC8.33% vs 8.99% median
    Revenue Growth (Trailing 4 Quarters, YoY)+3.60% vs +10.94% median
    Dividend Yield1.59% vs 0.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 1.15% and EPS growth at 0.19% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+1.15%
    EPS Growth Forecast (2Y CAGR)+0.19%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ELV

    What is ELV's market cap?

    Elevance Health has a market cap of $92.84B. Its enterprise value, which adds debt and subtracts cash, is $113.25B.

    What is ELV's P/E ratio?

    Elevance Health has a trailing P/E ratio of 14.3x and a forward P/E of 14.8x.

    How many shares of ELV are outstanding?

    Elevance Health has 216.06M shares outstanding. The count is down 2.78% from a year earlier.

    Does ELV pay a dividend?

    Yes. Elevance Health pays $6.88 a share a year, a dividend yield of 1.59%.

    How much debt does ELV have?

    Elevance Health has $30.76B of total debt and $10.35B of cash and equivalents, a net debt position of $20.41B.